A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle Cell Lymphoma|Bladder Cancer|Uveal Melanoma, Recurrent|Cervix Cancer|Carcinoma in Situ|Head and Neck Squamous Cell Carcinoma|Skin Cancer|Metastatic Cancer|Tumor, Solid|Tumor Recurrence
Interventions: DRUG: ONM-501|DRUG: Cemiplimab
Sponsor: OncoNano Medicine, Inc.